Concern widens over vaccines

SHANGHAI - Public concern over quality control at a pharmaceutical company in East China's Jiangsu province has widened from the rabies vaccine to the H1N1 vaccine.

The Hongkong-based Mingpao reported on Tuesday that the Ealong biotech company, located in Changzhou, used an "additive" when producing a rabies vaccine, which may affect more than 1 million people nationwide.

The substance reportedly allows vaccines produced by the company to meet inspection standards at a lower cost, while compromising the drug's potency. The adulteration was allegedly used in more than half of its vaccine products in recent years.